Dr. Leopold Bellak's (1977) editorial concerning a drug-free week following hospital admission was timely and important. A variety of pressures to medicate patients rapidly have usurped clinical judgment, often even precluding the diagnostic process. His discussion will be useful to investigators struggling to justify a drug-free period on inpatient units during which baseline data can be collected.
A parallel situation relevant to outpatient schizophrenics may assist the investigator in studying unmedicated patients without the cries of unethical conduct so often heard. Two clinical probabilities, and one possibility, converge to make lengthy periods off medication clinically acceptable, even to those who believe that maintenance neuroleptic medication is required in most or all schizophrenic patients. In the first place, it now appears likely that tardive dyskinesias have a significant prevalence in schizophrenic populations being treated as outpatients, perhaps in the range of 30 to 50 percent (Asnis et al. 1977, Chouinard 1977, and Sovner et al., in press ). In the second place, it is apparent that tardive dyskinesia, if detected early, may be a re-versible neurologic syndrome if medication is not continued (Crane 1975 , Jacobson and Baldessarini 1975 , Jus et al. 1976 ,.and Quitkin et al. 1977 . It" seems probable that many cases of early tardive dyskinesia are not detected because of the masking effect of dopamine-blocking drugs (Crane 1975 , Gardos 1977 , Gardos and Cole 1976 , Klawans 1973 ). These so-called "covert. dyskinesias" possibly represent a subgroup of early tardive dyskinesias potentially reversible with drug cessation.
Hence, clinical considerations alone justify substantial periods off medication for most patients exposed to prolonged treatment with dopamine-blocking drugs. A period of 4 to 6 weeks off medication would probably be sufficient to expose most cases of "covert dyskinesia." If these covert cases are, in large part, early stages of tardive dyskinesia, we have an opportunity to prevent irreversible neurologic complications.
It is to be hoped that psychiatrists will develop a tendency to keep patients off medication while initial evaluation and diagnoses are made, and to have lengthy drug-free periods for patients on maintenance antipsychotic drug therapy to evaluate neurologic complications. This may encourage more sophisticated clinical judgment regarding treatment of schizophrenic patients, may reduce the mistreatment of patients erroneously presumed to be schizophrenic, and will permit clinical investigators to reduce drug artifact in baseline and followup evaluations without being given to believe that they are inconsiderate of patient welfare.
